We examined chromosomes and molecular aberrations in 21 patients with therapy-related leukemias (t-AML) or myelodysplastic syndromes (t-MDS). All patients showed abnormal karyotypes, and chromosomal losses of No. 5 and/or No. 7 (−5/5q− and/or −7/7q−) were identified in 12 patients. Among these 12, six patients (50%) harbored a TP53 mutation, and two of five examined showed microsatellite instability, suggesting replication error (RER ؉ ) phenotype. Meanwhile, among the other nine patients without −5/5q− and/or −7/7q−, none harbored a TP53 mutation, and none of five examined showed RER ؉ phenotype. Thus, TP53 mutations and RER ؉ phenotype were preferentially associated with specific chromosomal losses in t-AML/MDS. We then screened for mutational events in representative DNA mismatch repair genes; exons 5-7 and 12-15 of the hMSH2 gene and exon 9 of hMLH1. Notably, two unrelated patients showing RER ؉ phenotype had an identical missense alteration at codon 419 of hMSH2 in their marrow cells and fibroblasts, which were not found in 120 DNA samples from healthy volunteers or patients with other hematological disorders. Consequently, this study revealed a possible relationship of RER ؉ phenotype accompanying an hMSH2 alteration to the development of therapy-related AML/MDS in association with TP53 mutations and specific chromosomal losses, and suggests that some patients may be predisposed to myelodysplasia after chemotherapy for their primary tumor.
Introduction
Acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS), developing after chemo-or radiotherapy for primary malignancies, are delineated as therapy-related leukemia (t-AML) and MDS (t-MDS). They are increasing in frequency in association with the improved prognosis of patients with a variety of malignancies, and t-AML accounts for approximately 10% to 20% of all AML. [1] [2] [3] Based on clinical features and cytogenetic findings, Pedersen-Bjergaard et al 3 proposed two major genetic pathways in leukemogenesis of t-AML/MDS. One is classical type therapy-related disorders which are closely associated with the administration of alkylating agents or irradiation, commonly present as myelodysplasia with unbalanced chromosome aberrations, mainly losses of chromosome 5q and/or 7q. The other comprises those with a history of treatment with topoisomerase II inhibitory agents such as epipodophyllotoxins and anthracycline antibiotics, demonstrating specific balanced chromosomal translocations involving bands 11q23 or 21q22. Chromosomal translocations at these bands involve the responsible genes, MLL and AML1, 4 and illegitimate recombinational events have been proven at the topoisomerase II cleavage sites adjacent to the breakpoint. 5, 6 The genetic mechanisms in leukemogenesis of t-AML/MDS with losses of specific chromosomes still remains obscure. Deletion of chromosome 5q, for example, although the deleted segment has been limited to the band 5q31 based on cytogenetic findings, contains three or more distinct regions which were proposed at the molecular level by several investigators. [7] [8] [9] In addition to chromosomal abnormalities, several molecular aberrations including mutational activation of protooncogenes and inactivation of tumor suppressor genes are thought to contribute to the development of t-AML/MDS, 2 but their accumulation in multistep pathogenesis is still controversial.
Recently, alterations of the length of simple repetitive genomic sequences (microsatellite instability; MSI) at more than two loci, named replication error positive (RER + ) or mutator phenotype, were shown to be characteristic features of cancer cells in hereditary nonpolyposis colorectal cancer (HNPCC), which is a representative cancer susceptibility. 10 This phenotype is closely associated with mutational inactivation of mismatch repair genes, 11, 12 and identified in 80-90% of multiple cancer patients. 13 Since t-AML/MDS arises as a secondary malignant disease following a primary tumor, patients with these disorders eventually develop multiple malignancies. A recent study actually revealed a high incidence of RER + phenotype in patients with t-AML, 14 although myeloid malignancies rarely occur in patients with HNPCC. 10 In this study, we summarize 21 patients with t-AML/MDS in respect of karyotypic abnormalities and the configuration of several genes to reveal characteristic features of genetic alterations, although RER status was examined only in limited cases. We also analyzed configurations of representative DNA mismatch repair genes to clarify the significance of RER + phenotype in therapy-related hematological disorders.
Patients and methods

Patients
We analyzed 21 patients with t-AML or t-MDS, whose profiles are shown in Table 1 . In 12 patients, the primary disorders were hematological diseases including malignant lymphoma, acute or chronic leukemia, multiple myeloma and polycythemia vera (five, three, two and two patients, respectively), 
Molecular genetics
Genomic DNA was extracted from each sample used for chromosome analyses by standard methods. N-RAS gene mutation was screened by modified allele-specific restriction enzyme analysis for codons 12 and 13, as we previously described. 17 Alterations of N-RAS at codon 61 and TP53 in exons 4 to 8 were examined by single strand conformation polymorphism (SSCP) analysis using a polymerase chain reaction (PCR) technique, as we described elsewhere. 17, 18 To identify FLT3 receptor gene duplication, PCR amplification of exon 11 of FLT3 followed by electrophoresis on 2% agarose gel was carried out, according to our previous report. 19 The mutations were confirmed by direct sequencing of every aberrant PCR product using 32 P-labeled sequencing primers and a T7 Sequencing Kit (Pharmacia, Uppsala, Sweden). Alternatively, we cloned the corresponding PCR product into a pCR1000 vector using a TA Cloning Kit (Invitrogen, San Diego, CA, USA), and sequenced it.
For detecting microsatellite instability (MSI), 12 independent mono-or dinucleotide microsatellites located on chromosomes 1p13 (BAT40), 2p21 (D2S123 and BAT26), 5q22 (APC), 5q31 (D5S399 and D5S624), 9p21 (D9S265), 11q22 (D11S35), 12p13 (D12S89), 17q12 (D17S250), 17p13 (TP53CA) and 18q21 (DCC) were examined. Among these, five loci (BAT40, D2S123, BAT26, APC and D17S250) were additionally examined to the loci we analyzed previously, 20 according to the recommendation by Dietmaier et al 21 with regard to their results in colorectal cancer. Using 100 ng (approximately 3 × 10 4 alleles) of each DNA sample, PCRmediated amplicon containing these microsatellites in the presence of 32 P-dCTP were electrophoresed on a denaturing 6% polyacrylamide gel, followed by autoradiography on Xray films. Fibroblast DNA samples were also obtained from cultured bone marrow aspirates in 10 patients as constitutional DNA. MSI was defined by a difference in band patterns between fibroblasts and marrow cells, and the reproducibility was confirmed by two or more experiments.
Screening for mutations of mismatch repair genes
For all 21 patients with t-AML/MDS, we examined mutations of mismatch repair genes; exons 5, 6, 7, 12, 13, 14, and 15 of the hMSH2, where mutations had been frequently described in HNPCC, 13 and exon 9 of hMLH1 in which a sole mutation had been proven in a cell line of hematological disorder. 22 PCR-SSCP was carried out for each exon using the corresponding sets of primers reported, 22, 23 and aberrantly migrating bands on SSCP analyses were sequenced. In addition, to detect allelic losses in hMSH2 locus, loss of heterozygosity (LOH) analyses at the D2S391 locus were performed according to the report by Baccichet et al.
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Results
Cytogenetic findings
Cytogenetic analyses revealed abnormal karyotypes in each of the 21 patients (Table 1) . Losses of the whole or the long arm of chromosome No. 5 (−5/5q−) or No. 7 (−7/7q−) were identified in seven and 11 patients, respectively, which were reported to be specific chromosomal losses in t-AML/MDS. 3 Among these, six showed both losses (cases 701, 703, 705, 707, 709, and 712), and thus 12 patients eventually harbored either a 5q− or −7/7q− or both. A deletion of 17p was also found in six patients, and a deletion of 12p in four (Table 2) . Translocations involving 11q23 were identified in six patients, four of whom showed a t(9;11)(p22;q23). Each patient had a t(8;21) and a inv(16) (Table1). Only two patients (cases 716 and 721) did not exhibit any of these specific abnormalities.
Molecular alterations in t-AML/MDS
Six of 21 (29%) patients showed a TP53 mutation in the coding region, but no-one showed an N-RAS mutation. A single patient (case 706) showed a tandem duplication of FLT3 receptor gene in the final sample obtained during his clinical course, who was included in our previous report and detailed. 19 Microsatellite instabilities (MSI) were identified in two (cases 701 and 702) of 10 patients whose fibroblasts were available as a control. Case 701 showed alterations of simple repetitive genomic sequences in D2S123 and BAT26, in addition to the loss of heterozygosity (LOH) at the loci of D12S89, D17S250, TP53CA, APC, D5S399 and D5S624. Primary ALL cells did not show MSI in this case (Figure 1) . Case 702 showed alterations in D5S399, D5S624, and D9S265 ( Figure 1 ). We could not analyze MSI status of his primary disorder because a DNA sample was not available in this case.
Here, we summarize these genetic alterations dividing our series of patients into two karyotypic groups (Table 2) ; one consisted of patients with specific chromosomal losses (−5/5q− and/or −7/7q−) (cases 701-712) and the other without these losses (cases 713-721), as suggested by Pedersen-Bjergaad et al. 3 Interestingly, TP53 mutations and replication errors were preferentially identified in those patients with 5q− and/or −7/7q− (six of 12 patients and two of five examined, respectively), while these alterations were not found in t-AML/MDS patients without −5/5q− or −7/7q− (nine and five examined, respectively). We compared above genetic events to our series of patients with de novo AML or MDS from our previous reports [17] [18] [19] [20] 25 and additional patients of recent study (Table 3) . TP53 mutations were significantly associated with 5q− and/or −7/7q− in both therapy-related and de novo cases. Replication errors were also preferentially found in chromosomal deletion cases to a lesser extent, whereas N-RAS and FLT3 mutations were not associated with these chromosomal losses. Significantly frequent compairing of two chromosomal categories using chi-square test (*, P Ͻ 0.05; **, P Ͻ 0.0001).
Configuration of mismatch repair genes
Screening of the hMSH2 gene revealed aberrant bands within exon 7 in three of 21 patients with t-AML/MDS (Figure 2 ). No abnormal band was detected in the other exons of hMLH2 and hMLH1. The mutations of hMSH2 were a CAG(Gln) to AAG (Lys) substitution at codon 419 in two patients (cases 701 and 702) (Figure 3) , and a CTT(Leu) to TTT(Phe) at codon 390 in the other (case 710). The former was confirmed to be a germline or an early somatic mutation, since both patients showed the same alteration in corresponding fibroblast DNA samples. To distinguish these missense mutations from polymorphism, we screened exon 7 of hMSH2 in 120 DNA samples obtained from 31 healthy volunteers, 33 patients with lymphoid malignancy, and 56 with a hematological nonmalignant disorder. The C to T transition at codon 390 was likely a natural polymorphism since it was found in 10 individuals including three healthy volunteers, as reported in the Japanese population (two of 80). 26 On the other hand, the C to A transversion at codon 419 was not found in any of the 120 samples. In addition, such polymorphism has not been reported so far. 13, 26 LOH analyses at hMSH2 locus revealed that five of 10 examined were informative heterozygotes for D2S391, and none of these five including case 701 showed LOH, suggesting that both alleles retained in informative cases (data not shown). Case 702 was not informative at the loci of D2S123 and D2S391.
Consequently, among the 33 patients with primary lymphoid tumors and eight primary lymphoid malignancies followed by t-AML/MDS, only two patients (701 and 702) harbored a mutation of hMSH2 and these patients exclusively developed therapy-related MDS after cytostatic therapy for their preceding lymphoid malignancies. Both patients also showed RER + phenotypes probably based on a mutation in a mismatch repair gene, and they had a complex karyotype with specific chromosomal deletions as well as a missense mutation of the TP53 gene. To our knowledge, these two patients were unrelated to each other within the third degree of generation, and their family history revealed no predisposition to cancer in their members.
Figure 3
Sequencing of exon 7 of hMSH2 in cases 701 and 702. Cloning to the vector and subsequent sequencing of marrow cell DNA revealed a C to A transversion of codon 419 in both patients, resulting in amino acid substitution of glycine to lysin. Although the A bands at the third nucleotide of codon 418 were faint in lanes 2-4, direct sequencing of marrow cells DNA of case 701 revealed a heterozygote for CAG/AAG at codon 419 without any other alterations.
Discussion
Among 21 patients with t-AML/MDS, we identified a partial or whole chromosomal loss of No. 5 and/or 7 in 12 patients, and a TP53 mutation in six. The TP53 mutation was preferentially detected in the category of t-AML/MDS with these chromosomal losses, and also associated with a complex abnormal karyotype including 17p monosomy as it has been reported previously in cases of de novo AML or MDS. 18, 25, 27 On the other hand, N-RAS mutations and FLT3 duplications were rare in t-AML/MDS irrespective of the association with losses of chromosomes No. 5 and/or No. 7, as well as in de novo AML or MDS (Table 3) . We previously presumed that N-RAS and FLT3 mutations do not play a significant role in the development of de novo cases, because of their low incidence and the late appearance, 17, 19, 28 and it seems to be the case in patients with t-AML/MDS.
Replication error (RER + ) phenotypes were identified in two of 10 patients examined, and both patients showed complex abnormal karyotypes including 5q− and/or −7/7q−. Patients with this phenotype preferentially showed these chromosomal losses in de novo cases as well, although the total number of samples fully analyzed is rather small to be conclusive. BenYahuda et al 14 also reported a frequent RER + phenotype in patients with t-AML, which was closely associated with a TP53 mutation and deletions of chromosome Nos 5 and/or 7. These findings suggest that the genetic basis of RER + phenotype, TP53 mutation, and specific chromosomal losses may play a key role in the development of t-AML/MDS. Somatic slippage of DNA polymerase during DNA replication results in microsatellite instability, and an accumulation of MSI in defective mismatch repair systems correlates with RER + phenotype. This mechanism is the source of progressive accumulation of mutations in critical genes. 29, 30 We hypothesize that a multistep pathogenic process is related to an accumulation of such alterations as specific chromosomal losses, karyotypic evolution, TP53 mutation, and MSI, in a proportion of t-AML/MDS. Our previous longitudinal analyses of these genetic alterations during the course of MDS did not clarify the very early events, 17, 19, 31 but TP53 mutation and MSI were detectable at relatively early phases of the disease. 18, 20 On the other hand, pathogenesis of t-AML with specific chromosomal translocations is relatively simple, in which topoisomerase II inhibitory agents generate a causative chimeric mRNA of corresponding translocations, and additional molecular alterations may arise thereafter.
In HNPCC, germline mutations in any of the DNA mismatch repair genes, mainly hMSH2 or MLH1, have been reported, which account for approximately 70% of kindreds, 11, 12 and most patients show RER + . 32 This phenotype is identified infrequently in sporadic cases of colorectal, gastric, endometrial, or ovarian cancers. 26, [33] [34] [35] In hematological disorders, we and other investigators have reported this phenotype in a subset of patients with blastic crisis of chronic myelogenous leukemia, 36 chronic lymphocytic leukemia, 37 T cell acute lymphoblastic leukemia, 22 and MDS, 20,38,39 although others reported rare RER + phenotype in myeloid leukemias. [40] [41] [42] Higher incidences of this phenotype in hematological malignancies were reported in Japanese and Israeli studies, 14, 36, 38 whereas a much lower incidence were reported in European studies. 24, 37, [40] [41] [42] This discrepancy may reflect a genetic susceptibility to RER + malignancies in different ethnic or geographic populations 12 or different therapeutic regimens for primary tumor. Alternatively, different methodology and interpretation for MSI may influence the results as several investigators have pointed out. 43, 44 In therapy-related AML, Ben-Yehuda et al 14 reported an extremely high incidence of MSI, 15 of 16 (94%) patients, and they emphasized that RER + phenotype predisposed the patients to the development of t-AML. Our study also revealed that two patients with t-MDS manifested the RER + phenotype, which was accompanied by a mutation in the coding region of the hMSH2 gene. Loss of DNA mismatch repair has been reported to be associated with resistance to a variety of anticancer agents by impairing the ability of the cell to detect DNA damage and by increasing the mutation rate throughout the genome. 45, 46 Once mismatch-repair-deficient cells are present in bone marrow, enrichment of these cells as a result of chemotherapy would be expected to accelerate the accumulation of additional mutations that contribute to selective growth advantage. 14, 45 This mechanism may lead to development of therapy-related leukemia as Claij et al 46 suggested.
Germline mutations of hMSH2 in HNPCC were mainly frameshift and nonsense mutations, which account for 60% and 23% of mutations, respectively. 12 Missense mutations, as identified in two of our cases, accounted for only 10%, and the pathogenicity of these mutations is difficult to assess. However, we assume the C to A transversion of codon 419 identified in our cases represents the same pathogenesis as assessed by Peltomaki et al. 12 First, the codon is evolutionarily conserved in yeast. 47 Second, this transversion was not detected in the normal population of our series nor in the population of 80 healthy Japanese volunteers. 26 Thirdly, we were able to segregate the disease phenotype; that is, 33 patients with lymphoid malignancy and 56 with nonmalignant hematological disorders did not harbor this alteration. Moreover, both t-AML patients with this genotype eventually showed RER + phenotype. Based on the recessive nature of RER + phenotype, 48 a common mechanism of inactivation of DNA mismatch repair is mutation of one allele followed by loss or mutation of the remaining wild-type allele. Because our two cases with an hMSH2 mutation were heterozygotes for codon 419 as indicated in Figures 2 and 3 , we carried out LOH analyses near the hMSH2 locus. Although five informative t-AML/MDS cases including case 701 did not show LOH, it is not an unexpected result, since LOH is not commonly observed at the hMSH2 locus. 24, 34, 49 Alternatively, a late somatic mutation in the unexamined region might occur in the remaining allele.
Although a mutation in fibroblasts DNA does not formally mean germline mutation without family studies, we assume that the germline or an early somatic mutation of hMSH2 at codon 419 is closely associated with the susceptibility to develop t-MDS in these two patients. We suppose this alteration is not related to development of the primary tumor, because ALL cells in case 701 did not show RER + phenotype. Further studies with a larger number of cases with RER + phenotype would be needed to interpret this important issue. Recent studies have revealed that several lymphoid tumor cell lines with RER + phenotype harbor mutations of hMLH1 22 or hMSH2, 50 however, mutations of mismatch repair genes in myeloid disorders have not been reported so far. To uncover which genetic configuration is related to susceptibility for therapy-related leukemia is of great importance to establish the most suitable therapeutic strategy for primary malignancy.
